The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling-Reference-Cited by-同舟云学术

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling

Published:2018-01-18 Issue:3 Volume:84 Page:490-500
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Netterberg Ida¹^ORCID,Karlsson Mats O.¹^ORCID,Nielsen Elisabet I.¹^ORCID,Quartino Angelica L.¹²,Lindman Henrik³,Friberg Lena E.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Biosciences; Uppsala University; Box 591 75124 Uppsala Sweden

2. Genentech, Department of Clinical Pharmacology; Genentech, Inc.; 1 DNA Way South San Francisco CA 94080 USA

3. Department of Immunology, Genetics and Pathology; Uppsala University Hospital; ing 78/79 75185 Uppsala Sweden

Funder

Stiftelsen Onkologiska klinikens i Uppsala Forskningsfond

Cancerfonden

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13477/fullpdf

Reference44 articles.

1. Management of febrile neutropaenia: ESMO clinical practice guidelines;Klastersky;Ann Oncol,2016

2. Risk models for predicting chemotherapy-induced neutropenia;Lyman;Oncologist,2005

3. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management;Crawford;Cancer,2004

4. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline;Flowers;J Clin Oncol,2013

5. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment;Assi;Support Care Cancer,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework;Cancers;2023-11-15

2. Systemic Inflammatory Response as a Prognostic Factor in Breast Cancer. Part I. Tumor-Promoting Inflammation. Serum Inflammatory Markers;Annals of the Russian academy of medical sciences;2022-12-28

3. Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer;Anticancer Research;2022-12

4. Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy;Supportive Care in Cancer;2021-11-23

5. From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics;Clinical Pharmacology & Therapeutics;2021-03-16